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A B S T R A C T
Immune-mediated inflammatory disorders (IMID) are a group of diseases that present inflammation as a major
pathogenic mechanism. They affect 15% of the population and pose a heavy socio-economic burden. Despite the
growing knowledge on the etiopathogenesis of these diseases and the marked improvement in their manage-
ment, there is a lack of predictive markers of IMID development or severity suitable for early diagnosis and
adjustment of treatment intensity. The possibility that certain circulating miRNA profiles could be used as
biomarkers of risk of development and/or severity of several autoimmune diseases has fuelled the interest in
using them to improve the selection of successful treatments. The multi-pronged approach proposed here sought
to reveal circulating miRNAs and miRNA signatures that could act as new predictive biomarkers of IMID de-
velopment and severity. Our results showed that the circulating levels of miR-19b and miR-26b were sig-
nificantly decreased (p < 0.001) in IMID patients compared to controls. Furthermore, receiver operating
characteristic (ROC) curve analysis showed that these miRNAs were suitable discriminators capable to identify
an IMID, with areas under the curve (AUC) of 0.85 and 0.83, respectively. In addition, we established that miR-
19a and miR-143 were significantly increased in IMID patients with severe disease (p < 0.05). In summary, our
findings identify two different miRNA signatures. One of them is associated with the presence of IMIDs and could
lead to the development of tools for their early detection. The second signature is able to discriminate between
mild and severe forms of these disorders and could be a putative tool to select patient candidates for a more
intense treatment.
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One of the most important characteristics of the immune system is
tolerance, which is the ability to recognise self-antigens and avoid im-
mune reaction against them. Immune tolerance is maintained by the
recognition of exposed self-antigens and by the inactivation or deletion
of autoreactive T and B lymphocytes. Autoimmune diseases result from
a breakdown of these central tolerance mechanisms, leading to T and B
cell-mediated tissue damage [1].
Immune-mediated inflammatory disorders (IMIDs) are a group of
chronic diseases that share an immune component characterised by
undesired activation of the immune system, and present inflammation
as a major pathogenic mechanism. Examples of IMIDs include psoriasis
(Ps), rheumatoid arthritis (RA), Graves' disease (GD), and Graves'
ophthalmopathy (GO), among others [2–6]. Collectively, their in-
cidence and prevalence has markedly increased over the last decades
affecting nearly 15% of the general population (Ps, 1–2%; RA,
0.5%–1%; GD, 1–2%). These diseases produce an enormous socio-
economic burden due not only to medical costs, but also to progressive
severe disability, influencing productivity and dependence of affected
subjects [7–9]. The total costs of these disorders have been estimated to
range from 1000 to 12,000€ per patient/year depending on the disease.
In addition, there is an increased risk of early death due to cardiovas-
cular complications and other co-morbidities [2,7,10,11]. The patho-
genesis of IMIDs is complex and they are considered as multifactorial
diseases. It is widely accepted that interactions between genetic back-
ground, immunity and the environment contribute to the breakdown of
tolerance and the development of autoimmunity characteristic of
IMIDs. Lately, a common goal in the management of IMIDs is to develop
early diagnosis methods and tailored treatments for individual patients
according to the severity of their disease. The identification of novel
biomarkers that could be used as potential therapeutic targets for au-
toimmune diseases entails searching for new tools to reverse the tol-
erance break and adjust treatment intensity.
MicroRNAs (miRNAs) are a class of non-coding RNA molecules
(19–25 nucleotides) that regulate gene expression at the post-tran-
scriptional level inhibiting mRNA translation or promoting its de-
gradation [12,13]. By targeting a plethora of mRNAs, miRNAs can si-
multaneously regulate multiple pathways and biological processes in
which one miRNA may regulate different genes while a certain gene can
be regulated by different miRNAs. Hence, it is difficult to discern the
specific function/effect of a specific miRNA. Studies using conditional
transgenic mouse models for genes involved in the miRNA biogenesis
pathway have provided data about the central role of miRNAs in the
regulation of the immune response [14–16]. MiRNAs fine-tune the ex-
pression of genes involved in the immune response, and dysregulation
of this process can lead to aberrant expression of different cytokines,
and therefore to inflammation and loss of immune tolerance to self-
antigens, which are a hallmark of common chronic inflammatory dis-
eases [17–19]. Since miRNAs can be detectable in body fluids, such as
serum or plasma, they have emerged as potentially useful biomarkers
for risk assessment, diagnosis and prognosis [20]. Although the way in
which an extracellular miRNA profile affects cell responses is hard to
establish, data suggest that circulating miRNAs could be very useful as
prognostic or diagnostic biomarkers for autoimmune diseases and of
great importance in the design of future biological therapies [19,21].
Specific profiles of circulating miRNAs have been associated with
different systemic autoimmune diseases including systemic lupus er-
ythematosus, systemic sclerosis, Ps, RA and autoimmune thyroid dis-
ease (AITD) [19,22–24]. However, in order to unravel miRNAs most
consistently associated with dysregulation of the immune system
leading to autoimmune disorders, we have studied the expression of
immunologically relevant miRNAs in serum samples from patients with
different IMIDs, as well as its possible correlation with disease severity.
From these data we have developed a signature model which can
contribute to an improvement in the detection of severe IMID forms
and/or to the identification of miRNAs as possible targets for drugs used
to treat IMIDs. A major strength of this research is that we have sear-
ched for markers that may not only be specific of each IMID, but that
also reveal common events present in several IMIDs, thereby studying
possible links between the different types of diseases.
2. Material and methods
2.1. Patients and sample collection
The BIOIMID project was approved by the Clinical Research Ethics
Committee of Hospital de la Princesa (CEIm Hospital Universitario La
Princesa, PI-734) and written informed consent was obtained from all
patients prior to inclusion, in accordance with the Declaration of
Helsinki.
A total of 78 subjects were studied: 20 healthy subjects, 19 patients
(18 females) diagnosed of GD with or without GO defined by the
EUGOGO (European Group on Graves Ophtalmopathy) criteria [25], 19
patients (14 female) classified as RA by the 2010 EULAR/ACR (Eur-
opean League Against Rheumatism/American College of Rheuma-
tology) criteria [26] and 20 (9 female) with Ps. The main clinical fea-
tures of patients and controls are shown in Tables 1 and 2.
Patients were classified as having mild or severe disease according
the following parameters for each group:
A) In the GO group, a cut-off value of 3 in the 7 point scale of the
clinical activity score (CAS) was used to diagnose active GO [25]. A
total of 9 patients had mild disease, and 10 patients had severe disease
with an active GO.
B) In the RA group, the 28-joint disease activity score (DAS28) was
used to asses severity; 9 patients were classified as having mild disease
(DAS28 < 2.6) and 10 as having severe disease (DAS28 > 5.1) [27].
C) In the Ps group severity was assessed using Psoriasis Area
Severity Index (PASI); 9 patients with PASI< 10 were classified as
having mild disease and 11 patients with PASI≥10 as having severe
disease.
Blood samples were collected before treatment prescription. Serum
was obtained by 10 min centrifugation (1500×g) of 10 ml of total
blood and stored at −80 °C until use at the Biobank of Instituto de
Investigación Sanitaria Princesa.
2.2. RNA extraction and RT-PCR
Serum miRNA isolation was performed as previously described
[22]. To test haemolysis in serum samples, the absorbance of free
haemoglobin at 414 nm was measured using a NanoDrop® ND-1000
spectrophotometer (Thermo Scientific), samples with a peak > 0.2
were discarded. RNA was purified from 200 μl serum samples using
miRCURY RNA Isolation Kit Biofluids (Exiqon), according to manu-
facturer's instruction. Briefly, lysis solution containing 1.25 μg/ml of
MS2 bacteriophage RNA (Roche Diagnostics) and the RNA spike-in
Table 1
Clinical features of patients with IMID classified according to disease severity.
Mild Severe Controls p-value
n 27 31 18 –








2.4 (0.4–97.2) 72 (2.6–174) NA 0.0698
Smokers (YES/
NO/EX)








Values show number for categorical values and median (interquartile intervals)
for continuous variables. F/M = female/male. BMI: Body Mass Index.
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templates UniSp2, UniSp4 and UniSp5 was added to 200 μl of serum.
RNA was purified on microRNA mini spin columns and stored at
−80 °C. The robustness of RNA isolation process was assessed using
miRCURY microRNA QC Panels (Exiqon). First-strand cDNA was gen-
erated using cDNA synthesis kit (Exiqon) and subsequent quantitative
Real Time PCR (q-RT-PCR) was performed in triplicates using mi-
croRNA LNA™ PCR primer sets (Exiqon). PCR was carried out in 384
well plates in a CFX384 Real-Time System (Roche). Samples from all
groups within an experiment were processed at the same time.
2.3. RT-PCR analysis
Based on their role in the immune response or dysregulated ex-
pression in autoimmune diseases we selected a group of miRNAs with
potential predictive value in the assessment of IMID severity including:
hsa-miR-10a, hsa-mir-19a-3p, hsa-miR-19b-3p, hsa-mir-21-5p, miR-
23a-3p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-29a-3p, hsa-miR-
93-3p, hsa-miR-101-3p, hsa-mir-125b-5p, hsa-miR-126-3p, hsa-miR-
127-3p, hsa-mir-142-3p, hsa-miR-143-3p, hsa-miR-146a-5p, hsa-miR-
150-5p, hsa-miR-155-5p, hsa-mir-191-5p, hsa-miR-210-3p, hsa-mir-
326, hsa-miR-451 (Supplementary Table 1). In addition, hsa-miR-103a-
3p and hsa-miR-30c-5p were included as possible normalisers [28].
Relative Quantities (RQs) were determined using the log base 2 values
of the Ct difference between miRNAs and UniSp2 spike-in. RQ values
were then normalised using the value of mir-103a expression (NRQ).
Identification of miR-103a as the more stable reference miRNA was
carried out as previously described [29]. Briefly, stability score (SSS)
was calculated for several miRNAs (Supplementary Table 2) by the
combination of different algorithms, including geNorm [30], Norm-
finder [31] and Coefficient of Variation [29]. Regardless of groups, the
expression of miR-10a, miR-127, miR-155 and miR-326 in serum was
very low or even undetectable (Ct > 40, Supplementary Figure 1).
2.4. Statistical analysis
Descriptive results were expressed as mean ± standard deviation
(SD), mean ± standard error of the mean (SEM), or median and 25–75
percentile, as appropriate. Pearson's bivariate correlations were per-
formed for all quantitative variables. Differences between groups were
compared using Chi-Square, Student T test or analysis of variance
(ANOVA) as appropriate. A transformation of variable was applied to
miRNA expression values to achieve a normal distribution in order to
apply parametric tests.
A Pearson's correlation matrix analysis was performed between all
miRNAs studied and the resulting pairwise correlation coefficients were
depicted as a heatmap for visual evaluation. Correlation values were
hierarchically clustered following Euclidean distances between objects
and complete linkage using superheat package in R version 3.5.1 [32].
Differences for each normalised miRNA between controls and IMID
groups were compared using a logistic regression model, adjusted by
age and sex, as recommended in previous reports [33]. The optimal cut-
off values of miRNA expression to determine low and high risk groups
were assessed using the maxstat R package [34]. Finally, receiver op-
erating characteristic (ROC) curve analyses were performed to assess
the classification power of each adjusted logistic regression model for
prediction of IMID or disease severity using pROC package in R version
3.5.1 [35]. The p-values were two sided, and statistical significance was
considered when p < 0.05. Data are presented with the specific p-
values: p < 0.05, p < 0.01 and p < 0.001. Box-plots were re-
presented using GraphPad Prism 4 software.
3. Results
3.1. Clinical characteristics of IMID patients
To identify common or specific circulating miRNAs for different
IMIDs, expression analysis was performed using RT-PCR assays in
serum samples from patients with GD (n = 19), RA (n = 19) and
psoriasis (n = 20), and from control subjects (n = 20). Clinical and
demographic characteristics of patients are shown in Tables 1 and 2 A
total of 27 patients had mild IMID whereas 31 had a severe disease.
Regarding demographic differences, the number of females was higher
in the IMID group because of the increased susceptibility of females for
these diseases, whereas no differences were detected in age between
patients with mild IMID (51.9 years, 34.2–64.3), severe IMID (49.66,
35–61.3) and controls (44.5, 27.7–56.7). Disease duration was slightly
higher in the severe group, although the difference did not reach sta-
tistical significance. Smoking conditions and body mass index (BMI)
Table 2
Clinical features of patients with Graves’ disease, Rheumatoid Arthritis and Psoriasis classified according to disease severity.
GD RA Psoriasis
Mild Severe Mild Severe Mild Severe
Gender (F/M) 9 9/1 5/4 9/1 6/3 3/8
Age (yr) 51 (40–73) 50 (33–58) 52.8 (34.3–54.1) 49.9 (34–62.1) 53 (42–68.5) 40 (32–45.5)
Disease Duration (months) 1.57 (0.86–4.1) 2.6 (0.3–5) 8 (3.9–16.9) 4.2 (3.1–6.3) 84 (0–156) 132 (96–198)
Smokers (YES/NO/EX) 2/6/1 4/5/1 4/1/4 0/7/3 2/6/1 5/3/3
BMI 24.5 (21.4–25.9) 21.9 (20.2–27.6) 26.1 (24.3–28.1) 29.4 (25.6–32.8) 27.5 (22.5–31.7) 26.5 (22.2–30.4)
Ophthalmopathy 0 10 – – – –
TSH mU/mL 0 (0–9.2) 0 (0–7.2) – – – –
T4 ng/dL 2.03 (0.47–4.8) 1.54 (0.56–4.7) – – – –
Tg-Ab UI/mL 20 (20–1076) 133 (20–1292) – – – –
TPO-Ab UI/mL 20 (20–565.5) 421 (20–2409) – – – –
TSHR-Ab U/L 1.81 (1.38–3.24) 3.9 (2.94–6.12) – – – –
DAS28 – – 2.1 (1.7–2.4) 6.2 (5.5–6.9) – –
HAQ – – 0.4 (0.1–0.5) 1.6 (1.1–1.9) – –
FR IU/ml – – 102 (25–188) 34 (27–101) – –
CCP 50 IU/ml – – 1472 (406–2070) 390.5 (327–498) – –
PASI 8.4 (6.2–9) 22.5 (16.45–35)
Values show number for categorical values and median (25–75 interquartile intervals) for continuous variables. GD (Graves' disease); RA (rheumatoid arthritis); F/
M = female/male; TSH, thyrotropin (Normal range = 0.27–4.20); T4, thyroxine (Normal range = 0.93–1.7); Tg-Ab, anti-thyroglobulin antibody (Negative< 344);
TPO-Ab, anti-thyroid peroxidase antibody (Negative<100); TSHR-Ab, anti-thyrotropin receptor antibody (Negative< 0.7). DAS28: 28-joint disease activity score;
HAQ: score from the Health Assessment Questionnaire (Spanish version) [64]; RF: Rheumatoid Factor (RF, assessed by nephelometry; positive> 20 IU/ml); CCP:
anti-citrullinated peptide antibody (CCP, measured by enzyme immunoassay [EIA]: Immunoscan RA, Euro- Diagnostica; positive> 50 IU/ml); BMI: Body Mass Index.
PASI: Psoriasis Area Severity Index.
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were also similar between groups. Then, the influence of clinical and
demographic variables on miRNA expression levels was analysed in the
control group, finding that 6 different miRNAs were significantly as-
sociated with age and sex, whereas there was no significant association
between any of the miRNAs analysed and BMI (Supplementary Figure
2). Thus, subsequent analyses were adjusted by sex and age as pre-
viously reported [33].
3.2. Expression of miRNAs in IMID patients
To identify potential miRNA groups in serum samples based on their
molecular expression profile, a Pearson's correlation matrix analysis
was carried out between normalised relative quantities of miRNAs.
Unsupervised hierarchical clustering showed two main clusters of
miRNAs that behaved in a different manner according to the correlation
of their expression profiles. Group A included miRNAs with homo-
geneous positive correlations, which could be divided in three sub-
clusters: A1 (miR-101, miR-19a, miR-23a, and miR-451), A2 (miR-29a,
miR-125 and miR-210) and A3 (miR-150, miR-27a and miR-143)
(Fig. 1). Group B showed heterogeneous expression correlations and
could be divided in 2 subclusters: B1 (miR-93, miR-19b, miR-26b, miR-
21 and miR-126) and B2 (miR-191, miR-30c, miR-142, and miR-146a)
(Fig. 1). These different expression profiles suggest that broad global
commonalities may exist between miRNA groups related to their post-
transcriptional regulation in IMID. Interestingly, group A tended to
show none or negative expression correlations with miRNAs from group
B.
In order to determine whether these different expression profiles
had a functional relevance, we first analysed differential miRNA ex-
pression between IMID patients and healthy subjects. Our data showed
that only the expression of the members of subcluster B1 miR-19b and
miR-26b was significantly decreased (p < 0.001) in the IMID group
compared with the control group (Fig. 2A and Supplementary Table 3).
The best NRQs cut-off for IMID discrimination were 0.356 for miR-19b
(p = 0.0001) and 0.0091 for miR-26b (p = 0.0008). ROC curve ana-
lyses for these cut-offs suggested that both miRNAs were moderate
Fig. 1. Correlation map between miRNAs in IMIDs. Graphical display of Pearson's correlation matrix between normalised relative quantities of different miRNAs in
serum samples from IMID patients. Correlation coefficient values (rho) arranged by hierarchical clustering are represented by a colour scale ranging from −0.19
(negative correlation, green) to 1 (positive correlation, red). The correlation matrix reveals two different clusters of miRNAs (A and B). (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
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discriminators between patients with IMID and healthy donors, being
the areas under the curve (AUC) 0.85 and 0.83 with high sensitivity
91.38% and 86.21% but low specificity 55.56% and 38.89, respectively
(Fig. 2B). Subsequent analysis of both miRNAs showed that combining
miR-19b and miR-26b in the regression model achieved the best pre-
dictive value for disease discrimination with an AUC of 0.89. Interest-
ingly, increased levels of both biomarkers had a protective effect on the
development of IMIDs [Odds Ratio (OR) = 0.05 and 95% confidence
interval (95%CI):0.01–0.22 for miR-19b and OR = 0.07 (95%CI:
0.02–0.3) for miR-26b]. Logistic regression model parameters are
summarised in Fig. 2B.
Finally, we analysed miRNA expression according to disease se-
verity (mild and severe IMID). The multivariate logistic regression
analysis revealed that expression of both the member of subcluster A1
miR-19a (p < 0.05) and the member of subcluster A3 miR-143
(p < 0.05) were significantly increased in patients with severe disease
compared to patients with mild disease (Fig. 3A and Supplementary
Table 4). AUCs for these miRNAs were 0.74 (95%CI: 0.6–0.87) and 0.75
(95%CI: 0.61–0.88), respectively (Fig. 3B). The best NRQs for dis-
crimination of severity were 0.93 for miR-19a (p = 0.05) and 0.085 for
miR-143 (p = 0.04). OR for these miRNAs were 7.6 and 12.54, re-
spectively, thereby indicating that their increased expression represents
a risk factor for developing a severe IMID. Interestingly, the composite
of both parameters had a better predictive value with an AUC of 0.81
and a percentage of prediction of 70.69%. Logistic regression model
parameters are summarised in Fig. 3B. Interestingly, miR-19a and miR-
143 are co-clustered (converge) in a closely related group of miRNAs as
shown in the global miRNA analysis (Fig. 1). These data suggest that
the dysregulation of some miRNAs could be a common factor to develop
a severe form of IMID.
4. Discussion
Accumulating evidence supports the use of miRNAs as prognostic
biomarkers of disease and as a valuable diagnostic strategy [36].
MiRNAs are specific and stable, and they are present in serum, thus they
could be useful as minimally invasive diagnostic tools for various dis-
eases as well as for research on novel therapeutic targets [37]. Since
miRNAs could play a role in maintaining immune tolerance and pre-
venting autoimmunity, in the present study we have analysed im-
munologically relevant miRNAs in different IMIDs including GD, Ps and
RA. A major strength of this research resides on the fact that we have
searched for markers that may not only be specific of each disease, but
that also reveal common events present in several IMIDs, thereby un-
veiling powerful, yet not obvious, links between the different types of
IMIDs. This is a very innovative approach to diagnosis, as previous
studies have usually focused on a specific IMID. In this sense, our results
can have important implications in managing all these related disorders
as a whole, since they would allow to evaluate the possibility of de-
velopment of different IMIDs on a certain patient.
In this study we have unveiled a distinctive miRNA profile, char-
acterised by significant downregulation of miR-19b and miR-26b, as a
possible regulator of IMID development. MiR-19b is part of the miR-17-
92 cluster, which regulates CD4+ T-cell antigen responses and pro-
motes Th17 responses [38–40]. Furthermore, miR-19b is down-
regulated in monocytes from patients with systemic lupus er-
ythematosus (SLE) and antiphospholipid syndrome (APS), in which is
important for the modulation of tissue factor expression [41]. MiR-26b
has also been shown to play a role in inflammation and inflammatory
cytokine secretion in RA and as an immune response modulator in os-
teoarthritis [42,43]. Furthermore, miR-26b targets the inflammatory
factor prostaglandin-endoperoxide synthase 2 (PTGS2) which plays
important roles in inflammatory diseases inducing the production of
prostaglandin E2 (PGE2) [44,45]. Interestingly, these two miRNAs
shared the same subcluster (B1) with miR-21 and miR-126, which
suggests that their functions may be closely interrelated. Indeed, miR-
21 has largely been associated with the development of autoimmune
diseases, playing important roles in the immune system [46]. However,
Fig. 2. Serum miRNAs associated with IMIDs. A) Expression (Normalised relative quantity, NRQ) of statistically significant miRNAs in serum samples from IMID
patients compared to controls. Results were analysed by a logistic model adjusted by age and sex. Data are presented as box-plots *P = 0.05. **P = 0.01.
***P = 0.001. B) Receiver Operating Characteristic (ROC) curve analyses performed to assess the diagnostic value of circulating miR19b, miR26b and the com-
bination of both to discriminate between controls and IMID patients. The table shows areas under the curve (AUC), percentages of correctly predicted cases, 95%
confidence intervals (95% CIs), sensitivities, and specificities of the analyses. Results of both models are given as crude odds ratios (OR, 95% CI), and odds ratios
adjusted by sex and age (adj. OR, 95% CI).
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we have not observed significant differences in the relative expression
of miR-21 and miR-126 in the IMIDs patients studied. This could be due
to the combination in our analysis of several IMIDs as a whole group or
to the comparison of all of them with controls. In this regard, previous
studies have reported discordant results in these two miRNAs in IMIDs,
with reports of decreased or increased expression depending of the
specific disease or type of sample analysed (Supplementary Table 1).
Although enough reports in the literature describe the comparative
profile of circulating miRNA levels between patients with individual
autoimmune diseases and healthy donors, limited information has been
published about miRNA profiles associated with specific phenotypes in
patients with IMID, especially regarding disease severity. In this regard,
we have described that two miRNAs (miR-19a and miR-143) belonging
to cluster A show increased levels in patients with severe disease
compared to those with mild disease. It is intriguing that the miRNAs
that differentiate patients from healthy donors (miR-19b and miR26b)
are located in a different cluster than those that differentiate severe and
mild disease. This suggests that the pathways involved in the devel-
opment of IMIDs can be different from those regulating their severity.
Regarding disease severity, our results showed an association be-
tween high levels of circulating miR-19a and miR-143 and patients with
higher inflammatory status. Some targets of these miRNAs are proin-
flammatory molecules, such as TNFα [47,48], TLR2 [49] and molecules
involved in MAPK signalling pathway [50], suggesting that miR-19a
and miR-143 could be involved in negative feed-back loops. This may
explain why miR-19a has been also associated with relapses of active
psoriasis and with other IMIDs not assessed in this study such as mul-
tiple sclerosis, and inflammatory bowel disease [51–53].
Regarding miR-19a and the other members of cluster A1 (miR-101,
miR-23a and miR-451), some of their targets also play anti-in-
flammatory or regulatory roles. These targets include the JAK/STAT
pathway inhibitors SOCS1 and SOCS3 [54,55], the NFκB pathway in-
hibitors IKKa (also known as CHUK) and IKBKB [56,57], phosphatases
like PTEN, which negatively regulates lymphocyte activation [58,59]
and DUSP1 [60,61] and the TGFβ related transcription factor SMAD4
[62]. Therefore, in some IMIDs in which the regulation of TNF or TLR
production or signalling is altered, the up-regulation of miR-19a and
some other members of its cluster can result in perpetuation of disease
with more severe forms due to down-regulation of anti-inflammatory
pathways.
This research, however, is subject to some limitations. On one hand,
cytokines have been described to modulate the expression of miRNAs
and, on the other hand, miRNAs can modulate the expression of cyto-
kines [63], thus it is difficult to determine about the causality of
miRNAs in IMIDs. To evaluate whether altered expression of miRNAs
are the cause or consequence of an IMID, it would be needed long-
itudinal studies in IMIDs patients, especially with samples and clinical
data before and after treatment. This approach would provide valuable
data on the contribution of our proposed miRNA signatures in the pa-
thogenesis and their roles as biomarkers.
To conclude, it is possible that miR-19b and miR-26b could be used
in the next future as promising diagnostic strategies for the prediction
of development of IMIDs. In addition, the combination of miR-19a and
miR-143 could serve as a biomarker to detect those patients with more
severe disease who need early treatment. Altogether they may serve as
a predictive signature for the future use of novel therapeutic targets for
a successful treatment of IMIDs.
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combination of the two miRNAs to discriminate between mild and severe disease. The table shows areas under the curve (AUC), percentages of correctly predicted
cases, 95% confidence intervals (95% CIs), sensitivities, and specificities of the analyses. Results of the models are given as crude odds ratios (crude OR, 95% CI) and
odds ratios adjusted by sex and age (adj. OR, 95% CI).
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